FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569887051> ?p ?o ?g. }

• W2569887051 endingPage "559" @default.
• W2569887051 startingPage "542" @default.
• W2569887051 abstract "The efficacy and safety of vedolizumab, a gut-selective α4β7 integrin antibody, were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80 years. We investigated the efficacy and safety of vedolizumab in patients stratified by age from the GEMINI trials. Safety and efficacy, including clinical response, clinical remission, and corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients aged <35, 35 to <55, and ≥55 years. At baseline, 353, 412, and 130 ulcerative colitis (UC) and 582, 443, and 90 Crohn’s disease (CD) patients were aged <35, 35 to <55, and ≥55. Of these patients, 56 were aged ≥65 years (UC: 33, CD: 23). Trends favoring vedolizumab over placebo were observed for most efficacy endpoints irrespective of patient age; some variability between subgroups was observed. Safety profiles of vedolizumab and placebo were similar in all age groups. Vedolizumab-treated patients aged ≥55 had the lowest incidence of serious infections (0.9 per 100 person–years) and adverse events leading to hospitalization (14.8 per 100 person–years). There were no age-related differences in the incidence of adverse hematological events, malignancy, or death. The safety and efficacy of vedolizumab in patients with UC or CD were similar for all age groups. The number of patients in the oldest age group in these analyses was small; thus further studies of vedolizumab in larger cohorts of elderly patients are warranted. Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.)." @default.
• W2569887051 created "2017-01-13" @default.
• W2569887051 creator A5005225915 @default.
• W2569887051 creator A5014859974 @default.
• W2569887051 creator A5036329878 @default.
• W2569887051 creator A5056934737 @default.
• W2569887051 creator A5064070610 @default.
• W2569887051 creator A5071070019 @default.
• W2569887051 creator A5089171412 @default.
• W2569887051 date "2017-01-09" @default.
• W2569887051 modified "2023-10-17" @default.
• W2569887051 title "Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age" @default.
• W2569887051 cites W1509905658 @default.
• W2569887051 cites W1607497471 @default.
• W2569887051 cites W1950799344 @default.
• W2569887051 cites W1965283604 @default.
• W2569887051 cites W1975378910 @default.
• W2569887051 cites W1987412927 @default.
• W2569887051 cites W1991151307 @default.
• W2569887051 cites W1991334020 @default.
• W2569887051 cites W1995338823 @default.
• W2569887051 cites W2004608617 @default.
• W2569887051 cites W2007139417 @default.
• W2569887051 cites W2016634557 @default.
• W2569887051 cites W2017149988 @default.
• W2569887051 cites W2024763754 @default.
• W2569887051 cites W2046772132 @default.
• W2569887051 cites W2070246874 @default.
• W2569887051 cites W2072171922 @default.
• W2569887051 cites W2085752173 @default.
• W2569887051 cites W2094681170 @default.
• W2569887051 cites W2100942700 @default.
• W2569887051 cites W2112635226 @default.
• W2569887051 cites W2131632358 @default.
• W2569887051 cites W2132978141 @default.
• W2569887051 cites W2160619682 @default.
• W2569887051 cites W2162805528 @default.
• W2569887051 cites W2169988437 @default.
• W2569887051 cites W2171340463 @default.
• W2569887051 cites W2284318219 @default.
• W2569887051 cites W2301614008 @default.
• W2569887051 cites W2326348131 @default.
• W2569887051 cites W2406797900 @default.
• W2569887051 doi "https://doi.org/10.1007/s12325-016-0467-6" @default.
• W2569887051 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5331094" @default.
• W2569887051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28070861" @default.
• W2569887051 hasPublicationYear "2017" @default.
• W2569887051 type Work @default.
• W2569887051 sameAs 2569887051 @default.
• W2569887051 citedByCount "67" @default.
• W2569887051 countsByYear W25698870512017 @default.
• W2569887051 countsByYear W25698870512018 @default.
• W2569887051 countsByYear W25698870512019 @default.
• W2569887051 countsByYear W25698870512020 @default.
• W2569887051 countsByYear W25698870512021 @default.
• W2569887051 countsByYear W25698870512022 @default.
• W2569887051 countsByYear W25698870512023 @default.
• W2569887051 crossrefType "journal-article" @default.
• W2569887051 hasAuthorship W2569887051A5005225915 @default.
• W2569887051 hasAuthorship W2569887051A5014859974 @default.
• W2569887051 hasAuthorship W2569887051A5036329878 @default.
• W2569887051 hasAuthorship W2569887051A5056934737 @default.
• W2569887051 hasAuthorship W2569887051A5064070610 @default.
• W2569887051 hasAuthorship W2569887051A5071070019 @default.
• W2569887051 hasAuthorship W2569887051A5089171412 @default.
• W2569887051 hasBestOaLocation W25698870511 @default.
• W2569887051 hasConcept C120665830 @default.
• W2569887051 hasConcept C121332964 @default.
• W2569887051 hasConcept C126322002 @default.
• W2569887051 hasConcept C142724271 @default.
• W2569887051 hasConcept C197934379 @default.
• W2569887051 hasConcept C204787440 @default.
• W2569887051 hasConcept C27081682 @default.
• W2569887051 hasConcept C2776207728 @default.
• W2569887051 hasConcept C2779134260 @default.
• W2569887051 hasConcept C2780479503 @default.
• W2569887051 hasConcept C535046627 @default.
• W2569887051 hasConcept C61511704 @default.
• W2569887051 hasConcept C71924100 @default.
• W2569887051 hasConcept C90924648 @default.
• W2569887051 hasConceptScore W2569887051C120665830 @default.
• W2569887051 hasConceptScore W2569887051C121332964 @default.
• W2569887051 hasConceptScore W2569887051C126322002 @default.
• W2569887051 hasConceptScore W2569887051C142724271 @default.
• W2569887051 hasConceptScore W2569887051C197934379 @default.
• W2569887051 hasConceptScore W2569887051C204787440 @default.
• W2569887051 hasConceptScore W2569887051C27081682 @default.
• W2569887051 hasConceptScore W2569887051C2776207728 @default.
• W2569887051 hasConceptScore W2569887051C2779134260 @default.
• W2569887051 hasConceptScore W2569887051C2780479503 @default.
• W2569887051 hasConceptScore W2569887051C535046627 @default.
• W2569887051 hasConceptScore W2569887051C61511704 @default.
• W2569887051 hasConceptScore W2569887051C71924100 @default.
• W2569887051 hasConceptScore W2569887051C90924648 @default.
• W2569887051 hasIssue "2" @default.
• W2569887051 hasLocation W25698870511 @default.
• W2569887051 hasLocation W25698870512 @default.
• W2569887051 hasLocation W25698870513 @default.

• next